Tonix Pharmaceuticals Announces Two Oral Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) on Prevention of Rejection in Kidney and Heart Allograft Transplantation at the 2022 American Transplant CongressGlobeNewsWire • 05/31/22
Monkeypox Stocks: SIGA, EBS and TNXP Move Higher on Smallpox Vaccines, TreatmentsInvestorPlace • 05/20/22
Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2GlobeNewsWire • 05/18/22
Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational HighlightsGlobeNewsWire • 05/09/22
Tonix Pharmaceuticals to Present at B. Riley Securities' 2022 Virtual Neuro & Ophthalmology ConferenceGlobeNewsWire • 04/25/22
Tonix Pharmaceuticals Announces Results of Retrospective Observational Database Study In Over 50,000 Long COVID PatientsGlobeNewsWire • 04/20/22